Compass Therapeutics publishes 2025 annual report
PUBT · 3h ago
Share
Listen to the news
- Compass Therapeutics 2025 annual report highlighted progress across four clinical-stage oncology antibody programs led by tovecimig (CTX-009).
- Tovecimig Phase 2/3 trial in second-line biliary tract cancer met primary endpoint with ORR 17.1% versus 5.3% for paclitaxel alone, p=0.031.
- Trial reached prespecified 80% overall survival event threshold in Q1 2026, with PFS and OS top-line results expected in April 2026.
- Pipeline updates included plans to start CTX-471 Phase 2 basket study in NCAM+ tumors in mid-2026.
- Program expansion continued with CTX-10726 entering Phase 1 following FDA IND clearance in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved